The expression level of CDKN2A (cyclin-dependent kinase inhibitor 2A) in TP53-mutated cancers is higher than in TP53-wildtype cancers in 13 different cancer types: BLCA, BRCA, LIHC, LUAD, PAAD, SARC, SKCM, UCEC, COAD, GBM, LGG, STAD, and THYM. Here, CDKN2A is linked to cancer.